Comparison of clinical performance and subjective outcomes between three trifocal intraocular lenses

Session Details

Session Title: Moderated Poster Session: Focus on Multifocal IOLs and Cataract Surgery
Session Date/Time: Friday 21/02/2020 | 14:00-15:00
Paper Time: 14:08
Venue: Poster Area


First Author: F.Ribeiro PORTUGAL
Co Author(s): T. Ferreira                 

Abstract Details

Purpose:

To compare clinical outcomes and subjective experience after bilateral implantation of three non-toric diffractive trifocal intraocular lenses (IOLs).

Setting:

Hospital da LUZ, LISBON, PORTUGAL; Universidade de Lisboa, Lisbon,Portugal

Methods:

In a prospective comparative case series, patients were randomly allocated to receive bilateral implantation of either the RayOne Trifocal (Rayner), the Finevision POD F (PhysIOL) or the Acrysof IQ PanOptix toric (Alcon) IOLs. At 3-month follow-up, the main outcomes were uncorrected and corrected distance (UDVA and CDVA), intermediate at 80 cm (UIVA and DCIVA), and near at 40 cm (UNVA and DCNVA) visual acuities, refractive outcomes, defocus curves and the presence of photic phenomena.

Results:

Each group comprised 30 eyes (15 patients). Mean monocular UDVA was 0.03 ± 0.11 logMAR(RayOne), 0.04 ± 0.08 logMAR (Finevision) and 0.06 ± 0.11 (Panoptix) (P = 0.399); DCIVA, 0.05 ± 0.13logMAR, 0.05 ± 0.10 logMAR and 0.06 ± 0.10 logMAR, respectively (P > 0.9999); DCNVA, 0.02 ± 0.12logMAR, 0.03 ± 0.11 logMAR and 0.02 ±0.11, respectively (P = 0.841). A similar MRSE was found in the three groups (P = 0.878). Depth perception issues were less severe with RayOne than with Finevision (P= 0.042) and the Panoptix (P = 0.047). There was no significant difference in other photic phenomena between groups.

Conclusions:

The studied IOLs provided equally good visual outcomes, with a trend with the RayOne and PanOptix IOLs for better visual acuity between -1.5 D and -2.0 D of defocus and less photic phenomena, especially depth perception issues. New trifocal IOLs represent a good option for patients with a desire to reduce the need for spectacles.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented